Madison Muller

Eli Lilly's headquarters sits behind a gate with the US flag raised

Eli Lilly to spend $27 billion to bolster U.S. drug manufacturing as Trump tariffs loom

By Madison Muller and Bloomberg

Semaglutide medications Wegovy and Ozempic are pictured

Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers

By Bloomberg, Madison Muller, and others

A hand is seen holding Ozempic.

Novo’s main Ozempic plant cited for quality lapses by FDA

By Madison Muller and Bloomberg

Sen. Bernie Sanders is seen pointing and speaking at the opening of a Senate committee hearing.

Bernie Sanders grills Ozempic maker over high prices, accuses company of endangering lives

By Madison Muller, Naomi Kresge, and others

Ozempic ‘very likely’ to have price slashed in US government negotiations

By Gerry Smith, Madison Muller, and others

A photo of the packet for anti-obesity drug Wegovy.

Wegovy reduced Covid deaths in obese patients, study finds

By Madison Muller and Bloomberg

INDIANAPOLIS, INDIANA – MARCH 17: A flag flies above the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. Lilly, a pharmaceutical company, employs more than 12.000 people in Indianapolis and more than 42,000 worldwide. (Photo by Scott Olson/Getty Images)

Lilly wins FDA approval for new drug to slow Alzheimer’s

By Madison Muller, Robert Langreth, and others

woman shows off old oversized jeans

Hims will follow its Viagra playbook and offer weight-loss drugs that are 85% cheaper than Wegovy—with Mounjaro and Zepbound in its sights next

By Madison Muller, Jessica Nix, and others

INDIANAPOLIS, INDIANA – MARCH 17: A flag flies above the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. Lilly, a pharmaceutical company, employs more than 12.000 people in Indianapolis and more than 42,000 worldwide. (Photo by Scott Olson/Getty Images)

Demand for weight-loss drug Zepbound is so strong that Eli Lilly is warning patients may leave pharmacies empty-handed

By Ike Swetlitz, Madison Muller, and others

Bernie Sanders

‘Outrageous’: Bernie Sanders has Ozempic demands after study says it costs just $5 per month to manufacture

By Madison Muller, Robert Langreth, and others

CEO of Novo Nordisk Lars Fruergaard Jorgensen is seen during the 6th edition of the “Choose France” Summit at the Chateau de Versailles, outside Paris on May 15, 2023. Since 2018, the Choose France Summit seeks to promote France’s economic attractiveness and encourage international investment across the country and brings together hundreds of leaders from the largest multinational corporations. (Photo by Ludovic MARIN / POOL / AFP) (Photo by LUDOVIC MARIN/POOL/AFP via Getty Images)

Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5

By Madison Muller, Robert Langreth, and others

A man walking in front of Sweetgreen

Meet the surprise winner of the Ozempic craze: a fast-casual chain selling $18 salads

By Madison Muller and Bloomberg

Patients given a monthly injection of Amgen’s drug, dubbed MariTide, lost up to 14.5% of their body weight in just 12 weeks, according to a small, early-stage study published Monday in the journal Nature Metabolism.

Experimental once-a-month weight loss injectable shows lasting results in early study

By Madison Muller and Bloomberg

The last time there was this much hype over a new drug was for Viagra, which was approved in 1998. Yet hurdles remain, when it comes to the ability of patients to access weight loss and anti-diabetes injectables like Zepbound and Wegovy: These drugs cost a lot, insurance coverage is spotty, and patients may need to take them indefinitely to avoid regaining weight.

Weight-loss injectables like Zepbound are making as big of a splash as Viagra, if not bigger. What you need to know about the ‘miracle drugs’

By Emma Court, Madison Muller, and others

North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030

By Simone Foxman, Madison Muller, and others